Johnny D. Powers Acquires 100,000 Shares of Zomedica Corp. (NYSEAMERICAN:ZOM) Stock

Zomedica Corp. (NYSEAMERICAN:ZOM – Get Rating) Director Johnny D. Powers bought 100,000 shares of the company’s stock in a transaction that occurred on Thursday, May 25th. The stock was purchased at an average price of $0.19 per share, for a total transaction of $19,000.00. Following the acquisition, the director now directly owns 1,600,000 shares in the company, valued at $304,000. The purchase was disclosed in a legal filing with the SEC, which is available through this link.

Zomedica Stock Performance

Shares of ZOM opened at $0.19 on Friday. Zomedica Corp. has a one year low of $0.15 and a one year high of $0.41.

Zomedica (NYSEAMERICAN:ZOM – Get Rating) last announced its earnings results on Wednesday, March 15th. The company reported ($0.01) EPS for the quarter. The firm had revenue of $6.16 million during the quarter, compared to the consensus estimate of $6.20 million. Zomedica had a negative return on equity of 7.31% and a negative net margin of 94.20%. On average, analysts predict that Zomedica Corp. will post -0.01 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its position in shares of Zomedica by 5.1% during the 3rd quarter. Vanguard Group Inc. now owns 46,329,005 shares of the company’s stock valued at $9,775,000 after acquiring an additional 2,252,651 shares in the last quarter. BlackRock Inc. boosted its position in shares of Zomedica by 5.6% during the 1st quarter. BlackRock Inc. now owns 13,418,299 shares of the company’s stock valued at $4,523,000 after acquiring an additional 707,993 shares in the last quarter. Cambridge Investment Research Advisors Inc. boosted its position in shares of Zomedica by 0.6% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 11,256,560 shares of the company’s stock valued at $2,383,000 after acquiring an additional 64,400 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Zomedica by 4.3% during the 1st quarter. Geode Capital Management LLC now owns 9,302,960 shares of the company’s stock valued at $1,969,000 after acquiring an additional 386,149 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new position in Zomedica in the second quarter valued at about $552,000. Institutional investors own 9.42% of the company’s stock.

About Zomedica

(Get Rating)

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals.